Evidence map›Paper›PMID 35579819›Full record

ArticleDrug safety2022

Leveraging Machine Learning to Facilitate Individual Case Causality Assessment of Adverse Drug Reactions.

Yauheniya Cherkas, Joshua Ide, John van Stekelenborg

Abstract read
PubMed Publisher
In one paragraph

Article in Drug safety, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. How is AI developing in pharmacovigilance?Therapeutic advances in drug safety · 2026
    Article
  10. Review
  11. Review
  12. Cultural Divergence in Psychedelic Use among Medical Students: An ESPAD-Adapted Survey among Poles and Iraqis.European journal of investigation in health, psychology and education · 2024
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Yauheniya CherkasJanssen R&D, Horsham, PA, USA. ycherka@its.jnj.com.
Joshua IdeJohnson & Johnson Consumer, Inc, Skillman, NJ, USA.
John van StekelenborgJanssen R&D, Horsham, PA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionCausality assessment of individual case safety reports (ICSRs) is an important step in pharmacovigilance case-level review and aims to establish a position on whether a patient's exposure to a drug is causally related to the patient experiencing an untoward adverse event. There are many different approaches for case causality adjudication, including the use of expert opinions and algorithmic frameworks; however, a great deal of variability exists between assessment methods, products, therapeutic classes, individual physicians, change of process and conventions over time, and other factors.

objectiveThe objective of this study was to develop a machine learning-based model that can predict the likelihood of a causal association of an observed drug-reaction combination in an ICSR.

methodsIn this study, we used a set of annotated solicited ICSRs (50K cases) from a company post-marketing database. These data were enriched with novel supplementary features from external and internal data sources that aim to capture facets such as temporal plausibility, scientific validity, and confoundedness that have been shown to contribute to causality adjudication. Using these features, we constructed a Bayesian network (BN) model to predict drug-event pair causality assessment. BN topology was driven by an internally developed ICSR causality decision support tool. Performance of the model was evaluated through examination of sensitivity, positive predictive value (PPV), and the area under the receiver operating characteristic curve (AUC) on an independent set of data from a temporally adjacent interval (20K cases). No external validation was performed because of a lack of publicly available ICSRs with causality assessments for drug-event pairs.

resultsThe model demonstrated high performance in predicting the causality assessment of drug-event pairs compared with clinical judgment using global introspection (AUC 0.924; 95% confidence interval [CI] 0.922-0.927). The sensitivity of the model was 0.900 (95% CI 0.896-0.904), and the PPV of the model was 0.778 (95% CI 0.773-0.783).

conclusionThese results show that robust probabilistic modeling of ICSR causality is feasible, and the approach used in the development of the model can serve as a framework for such causality assessments, leading to improvements in safety decision making.

Indexed as

Adverse Drug Reaction Reporting SystemsDrug-Related Side Effects and Adverse ReactionsBayes TheoremHumansMachine LearningPharmacovigilance

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.